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Intense efforts are being undertaken to understand the pathophysiological mechanisms
triggered after brain ischemia and to develop effective pharmacological treatments.
However, the underlying molecular mechanisms are complex and not completely
understood. One of the main problems is the fact that the ischemic damage is
time-dependent and ranges from negligible to massive, involving different cell types
such as neurons, astrocytes, microglia, endothelial cells, and some blood-derived cells
(neutrophils, lymphocytes, etc.). Thus, approaching such a complicated cellular response
generates a more complex combination of molecular mechanisms, in which cell death,
cellular damage, stress and repair are intermixed. For this reason, animal and cellular
model systems are needed in order to dissect and clarify which molecular mechanisms
have to be promoted and/or blocked. Brain ischemia may be analyzed from two different
perspectives: that of oxygen deprivation (hypoxic damage per se) and that of deprivation
of glucose/serum factors. For investigations of ischemic stroke, middle cerebral artery
occlusion (MCAO) is the preferred in vivo model, and uses two different approaches:
transient (tMCAO), where reperfusion is permitted; or permanent (pMCAO). As a
complement to this model, many laboratories expose different primary cortical neuron
or neuronal cell lines to oxygen-glucose deprivation (OGD). This ex vivo model permits
the analysis of the impact of hypoxic damage and the specific response of different cell
types implicated in vivo, such as neurons, glia or endothelial cells. Using in vivo and
neuronal OGD models, it was recently established that mTORC1 (mammalian Target of
Rapamycin Complex-1), a protein complex downstream of PI3K-Akt pathway, is one of
the players deregulated after ischemia and OGD. In addition, neuroprotective intervention
either by estradiol or by specific AT2R agonists shows an important regulatory role for
the mTORC1 activity, for instance regulating vascular endothelial growth factor (VEGF)
levels. This evidence highlights the importance of understanding the role of mTORC1
in neuronal death/survival processes, as it could be a potential therapeutic target.This
review summarizes the state-of-the-art of the complex kinase mTORC1 focusing in
upstream and downstream pathways, their role in central nervous system and their
relationship with autophagy, apoptosis and neuroprotection/neurodegeneration after
ischemia/hypoxia.
Keywords: signaling, PI3K-Akt, autophagy, stroke, neuroinflammation, neuronal stress response, glia stress
response, MCAO
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mTORC: ROLE IN ADULT CENTRAL
NERVOUS SYSTEM (CNS)
As mentioned previously, in this review we try to summarize
the state-of-the-art of the complex kinase mTORC1 in the
brain. We will present some general structural features,
and some of elements defined, so far, as belonging to this
complex.
We will recapitulate some of themost representative upstream
and downstream pathways and their role in central nervous
system. We will revise their connexion of mTORC1 with
autophagy, apoptosis and neuroprotection/neurodegeneration,
mostly focused on ischemia/hypoxia. We are aware that we can
only mention some of the published works, due to the lack of
space.
mTORC1/2 Structure and Function
Mammalian target of rapamycin (mTOR) is a protein with serine-
threonine kinase activity that is part of two different multiprotein
complexes which differ in some of their components and their
upstream and downstream signaling (Takei and Nawa, 2014;
Bockaert and Marin, 2015; Switon et al., 2017). This kinase
regulates essential aspects of cell function including growth,
differentiation, survival and energy homeostasis by harmonizing
anabolic and catabolic processes, with the aim of maintaining
cellular physiology.
Structurally, mTOR is a multi-domain protein comprised
of a C-terminal FAT domain (FATC), a C-terminal kinase
domain (KD), a rapamycin binding domain (FRB), a
transactivation/transformation-associated domain (FAT)
and an N-terminal domain which provides a site of regulatory
protein interaction (HEAT repeats) (Hwang and Kim, 2011;
Yang et al., 2013; Switon et al., 2017). This HEAT repeats domain
allows interaction between mTOR and regulatory-associated
proteins, forming two complexes known as mTORC1 and
mTORC2 which function as homodimers (Yip et al., 2010; Aylett
et al., 2016), and include common and specific proteins. The
common regulatory components of mTORC1/2 are mammalian
lethal with SEC13 protein 8 (mLST8), Tel two-interacting
protein 1 (Tti1), telomere maintenance 2 (Tel2), DEP domain-
containing mTOR-interacting protein (DEPTOR) and the kinase
mTOR (Yip et al., 2010; Switon et al., 2017). There are two
regulatory-associated proteins specific to mTORC1 [regulatory
associated protein of Tor (Raptor) and proline-rich AKT1
substrate 40 kDa (PRAS40)] whereas the characteristic proteins
of mTORC2 are rapamycin-insensitive companion of mTOR
(Rictor), mammalian stress-activated protein kinase-interacting
protein 1 (mSin1), and protein observed with Rictor (PROTOR).
Consequently, mTORC1 and mTORC2 differ not only in the
composition of their specific regulatory proteins but also in
their rapamycin sensitivity, mediated by FK506-binding protein
(FKPB12). In fact, FKPB12 is another mTOR-interacting protein
that, in presence of rapamycin, blocks the catalytic domain of
mTORC1, reducing its kinase activity. In contrast, mTORC2 does
not interact with FKBP12-rapamycin, and is thus rapamycin-
insensitive. Nevertheless, sustained treatment with rapamycin
inhibits mTORC2 activity, probably by sequestration of mTOR
protein or uncoupling of mTORC2 components such as SIN1
(Sarbassov et al., 2006; Chen and Sarbassov, 2011; Switon et al.,
2017).
The role of each regulatory protein in the activity of
mTORC1/2 is not completely understood. Studies using mLST8-
deficient mice have revealed that mLST8 is necessary to
maintain Rictor-mTOR but not Raptor-mTOR interactions,
and consequently perturbs mTORC2 but not mTORC1 activity
(Guertin et al., 2006). Tti1 and Tel2 are important components
for assembly and maintenance of mTORC1/2 activity, and
are also critical for mTOR stability (Kaizuka et al., 2010). As
DEPTOR is an endogenous inhibitor of mTOR, its abundance
modulates activity of mTORC1/2, and it is found to be
overexpressed in some cancer types (Peterson et al., 2009;
Liu et al., 2010; Catena and Fanciulli, 2017). PRAS40 is a
negative regulator of mTOR, preventing binding of mTORC1/2
to its substrate (Wang et al., 2007). Raptor is important for
mTORC1 assembly, regulates mTORC1 activity and localization,
and plays a key role in the recruitment of mTORC1 substrates,
the best-characterized of which are translational regulators
(Hara et al., 2002; Yonezawa et al., 2004; Aylett et al.,
2016). Whereas Rictor and mSin1 stabilize each other and
constitute the structural basis of mTORC2, Rictor also gives
mTORC2 substrate specificity (Dos et al., 2004). PROTOR
doesn’t affect mTORC2 assembly, but plays a role modulating
mTORC2 kinase efficiency (Pearce et al., 2007, 2011; see
Figure 1).
In addition to these regulatory proteins, mTORC1 activity
is regulated by phosphorylation of specific C-terminal Ser/Thr
residues, performed by different kinases such as: Akt, p70
ribosomal S6 kinase (p70S6K), AMP-activated protein kinase
(AMPK), and also possesses an autophosphorylation site (Chong
et al., 2013). Therefore, the activity of mTORC1 is highly
regulated indicating the importance of maintaining mTORC1
activity levels within a physiological range. Indeed, mTORC1
is considered to be a nutrient-sensitive complex that regulates
cellular growth, protein synthesis and autophagy, whereas
mTORC2 has been defined as a regulatory kinase of Akt/PKB and
thus a component of growth factor signaling, although mTORC2
has not been characterized as fully as mTORC1.
From a functional viewpoint, mTORC1 is localized at a
strategic position in signaling pathways. On one hand, its
activity is modulated upstream by several pivotal intra- and
extracellular metabolic and energetic factors including growth
factors, amino acids, cell energetic status and oxygen availability,
through different pathways (Weichhart, 2012; Dibble and
Cantley, 2015; Chen et al., 2017; Switon et al., 2017). Thus,
mTORC1 can be considered to be a molecular sensor for
essential information related to nutrient availability, growth
factors and energetic balance. Additionally, mTORC1 modulates
important cellular processes such as translation, transcription,
lipid synthesis, autophagy and the cell cycle (Pla et al., 2016;
Ben-Sahra and Manning, 2017; Hong et al., 2017; Liu et al.,
2017).
It is currently accepted that activation of the kinase activity of
mTOR increases the rate of protein synthesis by both activating
the processes of translation initiation and elongation in cells. In
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FIGURE 1 | mTOR Functional domains and composition of mTORC1 and mTORC2. Graphical representation of the main functional domains of mTOR protein. mTOR
contains at C-terminal a FAT domain (FATC), the kinase domain (KD), a rapamycin binding domain (FRB) and a transactivation domain-associated protein domain
(FAT). The N-terminal domain is composed by a HEAT repeats site with a key role in the interaction with regulatory proteins permitting the formation of mTOR complex
(mTORC1 right and mTORC2 left). Representation of the mTORC1 and mTORC2 complex Both complex are formed, so far, by five common proteins and two/three
specific proteins. The common components of both complexes are in gray (Tti1; mLST8; Tel2; Deptor in gray). Whereas Raptor and PRAS40 are present in mTORC1
(green), and Rictor, Protor and mSin1 are part of mTORC2 (yellow).
fact, two of the best know targets of mTORC1, p70S6K and 4E-
binding proteins (4EBPs), have important roles in two phases
of the translation machinery: initiation and elongation (Chong
et al., 2013).
mTORC1/2 and CNS
Expression of mTOR in the adult brain is high, predominantly
in neurons but also in glial cells (Perluigi et al., 2015). However,
most of the knowledge regarding the neurologic role of mTORC1
comes from studies using neurons, and only limited information
related to glial cells is available. In neurons, mTORC1
activity is modulated by neuron-specific molecules including
neurotransmitters (e.g., glutamate, dopamine, serotonin, GABA,
cannabinoids), and neurotrophic factors [e.g., brain-derived
neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-
1)] (Bermudez-Silva et al., 2016; Chen et al., 2017). Some
important processes related to development and maturation of
the CNS are controlled by mTORC1 including neurogenesis,
axonogenesis, axon guidance, dendritogenesis, and growth of
dendritic spines (Jaworski and Sheng, 2006). In addition,
mTORC1 plays a key role in adult brain physiology and
pathology, influencing higher brain functions such as learning,
memory (Jaworski and Sheng, 2006), feeding behavior (review
in: Cota et al., 2006; Woods et al., 2008), synaptic plasticity
(Bockaert and Marin, 2015), cognition (Burket et al., 2014),
circadian rhythm (Jouffe et al., 2013) and sensorial perception by
modulation of sensitivity to peripheral sensory afferents (Obara
and Hunt, 2014).
Similarly, mTORC1 plays a role in gliogenesis during brain
development (Cloëtta et al., 2013), and has also been implicated
in differentiation and maturation of several glial cell types in
the adult brain, especially in oligodendrocytes and microglia
(Tyler et al., 2009). Recent data emphasizes the role of
mTORC1 in the control of lipid biosynthesis in oligodendrocytes
and Schwann cells, through sterol regulatory element-binding
proteins (SREBPs). Consequently, its contribution to correct
peripheral nerve function is related to velocity of action potential
conduction and precise brain myelination (Norrmén et al., 2014;
Zou et al., 2014). The role of mTORC1 in the balance of M1/M2
microglia phenotype has been reported (Chen et al., 2016),
and reduction of mTORC1 activity decreased pro-inflammatory
cytokines and chemokine synthesis, reducing the M1 microglia
phenotype (Li et al., 2016). Also, mTORC1 has been found to be
important for survival and size preservation of astrocytes (Pastor
et al., 2009).
Taking into account the broad cerebral functions regulated by
mTORC1 and its central position in cellular energetic/metabolic
homeostasis, dysregulation of its activity (increasing or
decreasing) would be detrimental for normal brain physiology.
Recent evidence supports that modification of mTORC1 activity
can trigger diseases of the nervous system, since disruption in
mTORC1 signaling affects multiple pathways including energy
production, mitochondrial function, cell growth, glucose/lipid
metabolism and autophagy.
Mutations in the genes encoding different molecular
components of mTORC1 or its related signaling pathways result
in diseases characterized by severe neurological symptoms
including epilepsy, tumor growth, autism and cognitive
disability. Use of transgenic animals has enabled correlation
of mTORC1 dysregulation with neurological indicators (for a
revision see Switon et al., 2017). Some human genetic disorders
have been associated with disturbed mTORC1 activity, including
Tuberous Sclerosis complex, currently considered mTORopathy.
It is a multi-system autosomal-dominant disorder characterized
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by benign tumors in some systemic organs, cortical and
cerebellar tuber, subependymal nodules, retinal hamartomas,
and hypomyelination (Carson et al., 2015; Mühlebner et al., 2016;
Hodgson et al., 2017). Clinical manifestations include epilepsy,
mental disability and autism (Zaroff et al., 2004; Mühlebner
et al., 2016). This disorder is caused by mutations in TSC1 and
TSC2 that encode Tuberous Sclerosis Complexes (Tsc1 and Tsc2)
that belong to the canonical pathway of mTORC1 activation
by trophic factors (see below), whereas these Tsc1/2 mutations
induce mTORC1 hyperactivation.
Neurofibromatosis is caused by mutations in the gene
that encodes neurofibromin, a modulator of mTORC1 activity
(Giovannini et al., 2014). It is characterized by the appearance
of tumors in the central and peripheral nervous system and
anomalies in other tissues (skin, kidney, and bone). Clinical
symptoms consist of learning disabilities, epilepsy and anxiety
among other. Analysis of human samples has demonstrated that
mTORC1 is over-activated, though administration of rapamycin
in in vitro and in vivo models reduced the severity of tumors
without toxicity (Giovannini et al., 2014).
In the adult brain, maintaining a precise balance of protein
translation and degradation (proteostasis) is fundamental
to avoid accumulation of toxic protein aggregates and
oxidized proteins that might trigger brain degeneration,
such as in Alzheimer’s disease (AD), Parkinson’s (PD), or
Huntington’s (Ht). Indeed, mTORC1 is an important player
in proteostasis, through its capacity to control translation and
autophagy.
In some neurodegenerative disorders such as AD or PD,
characterized by the anomalous accumulation of aggregated
misfolded proteins, data strongly suggests an anomalous level of
mTOR-dependent autophagy. In fact, the reduction of autophagy
with aging is a key mechanism that may contribute to the
accumulation of protein aggregates in neurons (for a review
see: Dazert and Hall, 2011; Perluigi et al., 2015). Following this
hypothesis, it has been demonstrated in some animal models of
AD orHt that administration of rapamycin promotes elimination
of toxic, misfolded proteins through induction of autophagy,
reducing disease severity (Spilman et al., 2010; Kiriyama and
Nochi, 2015; Benito-Cuesta et al., 2017).
Cerebral ischemia is an unexpected injury that may trigger,
among other things, neuronal and glial cell death, and later
neuronal degeneration (explained in detail below).
Our “working hypothesis” is that mTORC1 may play
an important role in limiting ischemic damage. Several
evidences sustain this assumption: (i) mTORC1 has the capacity
to control anabolic/catabolic cell processes; (ii) mTORC1
potentially modulate neuronal apoptosis and autophagy; and
(iii) considering the role of mTORC1 promoting neurogenesis
and improving angiogenesis. Consequently, we propose
mTORC1 as a potential therapeutic target for ischemic
stroke.
In this review, we discuss the role of mTORC1 with an
emphasis on the current knowledge about its impact in brain
ischemia, analyzing recent evidence from both in vivo and in vitro
models of cerebral ischemia.
SIGNALING PATHWAYS UPSTREAM OF
mTORC1
The level of activation of mTORC1 depends on integration of
extracellular signals through different pathways, permitting the
combination of multiple events to generate a suitable response in
order to maintain cellular homeostasis. In this section we explain
the key players in signaling upstream of mTORC1.
The Canonical Pathway: PI3K/Akt/mTOR
As a general rule, growth factors bind to two types of
receptors, Tyrosine kinase receptors (RTKs) or G-protein-
coupled receptors (GPCRs). Downstream of both, activation of
class I PI3-kinase is an essential step for initiating the signaling
cascades. The activation of this lipid kinase generate a plethora of
responses such as PDK1/Akt pathway, among others.
It is well known that complete activation of Akt requires
the action of two different kinases (pyruvate dehydrogenase
kinase 1, PDK1 and mTORC2) at two respective amino acid
residues: Thr308 and Ser473 (Zhao et al., 2006; Dibble and
Cantley, 2015). Downstream, Tsc has been identified as the
connection between Akt and mTORC1, and is formed by three
proteins: Tsc1, Tsc2, and TBC1D7 (Dibble and Cantley, 2015).
Tsc1 (also called Hamartin) is a stabilizing factor of Tsc2. While
Tsc2 (named Tuberin) is a guanosine triphosphatase (GTPase)-
activating protein (GAP) toward Ras homolog enriched in brain
protein (Rheb).
Akt phosphorylates Tsc2 and induces its dissociation from
Tsc1 (Dibble and Cantley, 2015). Activation of Tsc1/2 inactivates
the GTPase Rheb, which functions as a molecular switch by
alternating between GTP and GDP-bound forms (Parmar and
Tamanoi, 2010). GTP-Rheb directly activates mTORC1 (Malik
et al., 2013), but Tsc1/2 action converts GTP-Rheb into GDP-
Rheb, inactivating mTORC1. The loss of Tsc1/2 function is a
determinant of mTORC1 over-activation that results in brain
disease independent of growth factors (Frindlay et al., 2005;
Hwang and Kim, 2011). Tsc2 activity can also be regulated by
kinases such as mitogen-activated protein kinase (MAPK) and
AMP-activated protein kinase (AMPK). In fact, AMPK activated
by low cellular energy status (increased ratio of AMP/ATP)
can phosphorylate Tsc2 at different residues than Akt; whereas
phosphorylation of Thr1462 or Ser664 by Akt or MAPK,
respectively, inhibits Tsc and activates mTORC1 (Ma et al., 2007),
phosphorylation of Ser1345 or Ser1337/Ser1341 by AMPK or
GSK3β, respectively, increases Tsc1/2 activity and consequently
inhibits mTORC1 (Inoki et al., 2006; Takei and Nawa, 2014).
Thus, the AMPK-dependent pathway counterbalances the
effects of trophic factors on mTORC1 activity as long as cellular
energy is below an “optimal level” for survival.
Hormones, Growth Factors and
Neurotransmitters
Hormones and growth factors like insulin, IGF-1, epidermal
growth factor (EGF), neurotrophins [NGF, BDNF and
neurotrophin 3/4 (NT-3; NT-4)], or some neurotransmitters,
induce activation of downstream effectors of PI3K, Akt and
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subsequently mTORC1, through binding of specific membrane
receptors (Switon et al., 2017; see scheme in Figure 2). Whereas,
insulin/IGF-1 and neurotrophins are the best characterized
growth factors that activate mTORC1 complexes by the
PI3K/Akt pathway (Takei and Nawa, 2014; Chen et al., 2017).
In the nervous system, axonal guidance molecules such as
Reelin, Semaphorin, Ephrins, and Netrin-1 have been shown to
activate mTORC1 through PI3K/Akt, and also some neuronal
receptors like Glu receptors, cannabinoid receptors (CBRs),
angiotensin receptors (AT2R), and µ-opioids, among others
(Polakiewicz et al., 1998; Page et al., 2006; Puighermanal
et al., 2009; Mateos et al., 2016). In some cases, this
activation mediates important brain processes such as synaptic
plasticity.
Amino Acids
Besides growth factors, some amino acids (not only
glutamate and aspartate as neurotransmitters) have pivotal
roles in the regulation of mTORC1 activity. Experimental
evidence suggests that amino acids, particularly leucine,
serve as extracellular stimuli that modulate mTORC1. The
connection between mTORC1 and amino acid levels is the
Rag family of small G-proteins (Rag A-D) (Kim et al., 2008;
Sancak et al., 2008). RagA-D proteins are heterodimers
that locate to the lysosome surface, an important site of
mTORC1 activation. The active conformations of this
GTP/GDP binding protein class are GTP-RagA/B and
GDP-RagC/D (Dibble and Manning, 2013; see scheme in
Figure 2).
A reduction of amino acid availability induces the GDP-
RagA/B form, which triggers detachment of Rag from the
lysosomal surface and consequently inactivates mTORC1. In
contrast, when amino acid supply is sufficient, Rag binds
GTP and undergoes conformational change, directly binding to
Raptor and recruiting mTORC1 to the lysosomal membrane
(Jewell et al., 2013). This situation allows close proximity between
mTORC1 and Rheb on the lysosome surface, which can activate
mTORC1. However, the mechanism by which other amino acids
may modulate mTORC1 activity is not completely understood
(Saxton and Sabatini, 2017).
FIGURE 2 | Upstream regulators of mTORC1. Schematic representation of the different upstream pathways of mTORC1. The canonical pathway regulated mTORC1
activity through RTK/GPCRs receptors via modulation of PI3K/PDK1/Akt/TSC/Reb. This pathway may be positively regulated by growth factors, hormones and some
neurotransmitters, and negatively regulated by AMPK. AMPK is activated in situations of low energy and/or hypoxia resulting in an inhibition of mTORC1 activity that
may occurs at two levels. One by direct Raptor phosphorylation, that result in an inhibition of mTOR activity (red arrow); and second modifying TSC/REDD1 complex
by phosphorylation. In addition, amino acids levels could modulated mTORC1 activity directly at the lysosome surface (an important place for activation of mTORC1)
by modulation of heterodimers Rag A-D. Black arrows represent activation and red arrows represent inhibition.
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Nutrients, Energy Status and Stressful
Conditions
Energetic status, nutrient availability, and related stress
conditions such as glucose deprivation, hypoxia, and DNA
damage can modify mTORC1 activity (Shimobayashi and
Hall, 2014). In the brain, both glia and neurons use glucose
as a primary energy source, and are thus highly sensitive
to fluctuations in blood glucose levels (Poels et al., 2009).
Hypoglycemia may diminish ATP levels in glia/neurons and
increase reactive oxygen species (ROS), triggering AMPK and
promoting metabolic reprogramming. As discussed before,
AMPK is sensitive to cellular energy status, sensing the
AMP/ATP ratio and directing mTORC1 to modulate Tsc1/2 as
a compensatory mechanism to preserve cellular energy pools.
Activation of AMPK inhibits mTORC1 activity by two pathways,
each of which involves phosphorylation of different substrates:
Tsc2 and Raptor (Agarwal et al., 2015).
Similarly, a reduction in oxygen availability (hypoxia) inhibits
mTORC1 through multiple pathways, especially when hypoxic
conditions are sustained over time. Hypoxic activation of
Tsc complex occurs by two pathways, one being AMPK-
dependent, and the other acting via REDD 1. The increment
in REDD1 after hypoxia is enough to liberate Tsc2 from
chaperone 14-3-3 and permit its association with Tsc1. Hypoxic
conditions may also reduce mTORC1 activity through other
proteins that interfere with Rheb/mTORC interaction, including
promyelocytic leukemia tumor suppressor (PML) and hypoxia-
inducible proapoptotic protein BNIP3 (Brugarolas et al., 2004;
Wouters and Koritzinsky, 2008; see scheme in Figure 2).
In summary, the precise impact of amino acids, glucose,
growth factors, and neurotransmitters on mTORC1 activity in
both physiological and pathological brain situations is not fully
understand. This is partly because there isn’t much information
about the effects of selective elimination of each factor; thus, more
work must be performed in cellular and animal models to clarify
this issue.
SIGNALING PATHWAYS DOWNSTREAM OF
mTOR
The ability of mTORC1 sensing energy and nutrient levels makes
it a central node in regulation of metabolism. In nutrient-
rich conditions, mTORC1 kinase activity promotes anabolic
pathways (translation, transcription and lipid synthesis) and
downregulates cellular catabolic processes (protein degradation).
Anabolic Metabolism Regulated by
mTORC1
The best-identified anabolic process mediated by mTORC1 is
protein synthesis, which consumes large amounts of energy and
consequently is highly regulated. Activation of mTORC1 (when
cellular nutrient and energy levels are optimal) favors protein
synthesis. As mentioned previously, p70S6K and 4EBPs are key
targets of mTORC1, and are phosphorylated at various sites
(p70S6K1 at Thr389; 4EBP at several sites), favoring 5′ cap-
dependent mRNA translation. In addition, mTORC1 upregulates
several steps of ribosome biogenesis including transcription of
ribosomal RNA and ribosomal protein synthesis (Iadevaia et al.,
2014). Correct generation of ribosomes is necessary for cellular
protein synthesis in general, which is critical for cell survival.
Recently, several studies have focused on the role of mTORC1
in mRNAs translation location-dependent. As neurons are long
cells, some proteins must be produced locally on demand
at synapses, sometimes far away from cellular soma. This is
an important process that contributes to synaptic plasticity
(Jaworski and Sheng, 2006; Urbanska et al., 2012). Transcripts
activated by mTORC1 in response to BDNF have been described
in synaptoneurosomes prepared from cortical neurons, some
encoding proteins with important roles in dendritic spines (Panja
and Bramham, 2014).
Stress factors such as glucose reduction and insufficient amino
acids induce inhibition of mTORC1, promoting diminished
phosphorylation of 4EBP1. In such conditions, 4EBP1 associates
with the cap-binding eukaryotic translation initiation factor 4E
(EIF4E), which prevents EIF4E/EIF4G interaction and therefore
prevents cap-dependent translation (Wouters and Koritzinsky,
2008). In conclusion, mTORC1 has a pivotal role modulating
5′ cap-dependent translation, but also mediates translation
independently of this canonical pathway. A role has been
described for mTORC1 in cap-independent translational control
of some critical factors in the brain such HIF-1α, VEGF, and
IGF2 (Dai et al., 2011), a mechanism that would maintain
expression of important factors during stressful situations. This
cap-independent translation happens despite the absence of
mTORC1 phosphorylation of signal transducer and activator
of transcription 3 (STAT3), which diminishes the transcription
of some proteins that use the cap-independent translation
mechanism (Dodd et al., 2015).
In addition to its effect on protein synthesis, mTORC1 induces
de novo nucleotide synthesis through different mechanisms
(for a review, see: Ben-Sahra and Manning, 2017). Nucleotide
synthesis is not only necessary for ribosome biogenesis but
also for cell growth; several reports have indicated that the
impact of mTORC1 on nucleotide synthesis is mediated by
p70S6K1-dependent phosphorylation (Ben-Sahra et al., 2016).
mTORC1 also activates SREBP, a transcription factor that induces
expression of genes involved in fatty acid and cholesterol
biosynthesis. This is essential to supply lipids for membrane
elongation in growing cells, not only in neurons but also in glial
cells and oligodendrocytes for myelination of the nervous system
(Norrmén et al., 2014).
All of this evidence shows that mTORC1 tightly coordinates
the biosynthesis of the three key macromolecular components of
the cell through parallel pathways (see scheme in Figure 3).
Catabolic Metabolism Regulated by
mTORC1
Autophagy is the catabolic mechanism by which dysfunctional
or unnecessary cellular components are degraded through the
action of lysosomes (Mizushima and Komatsu, 2011; Boya et al.,
2013), and three major subtypes have been described: chaperone-
mediated autophagy, microautophagy and macroautophagy.
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FIGURE 3 | Downstream of mTORC1. mTORC1 play a key role integrating information about the availability of some important metabolic factors. This figure
represents the main mTORC1substrates described until now: P70S6K, EBPs, ULK complex and PI3KIII and their relationship. Black arrows represent activation and
red arrows represent a inhibition.
Macroautophagy consists of the formation of an isolated
membrane to sequester a portion of cytoplasm within a double
membrane vesicle or autophagosome, which subsequently fuses
with the lysosome to degrade its content. Apart from the
upregulation of macromolecule synthesis, mTORC1 is also able
to suppress catabolism, mostly via macroautophagy (hereafter
referred to simply as autophagy).
mTORC1 inhibits autophagy through several mechanisms,
the first of which involves its phosphorylation of ULK1/2
and ATG13, dissociating and inactivating the pro-autophagy
complex ULK [composed of ULK1/2, ATG13, ATG101 and RB1-
inducible coiled-coil protein 1 (RB1CC1)/FIP200]. Secondly,
mTORC1 can phosphorylate ATG14 and UVRAG, which
inactivates phosphatidylinositol 3-kinase class III (PI3KCIII)
complex during initial (composed of PIK3C3/Vps34, Beclin-
1, PIK3R4/Vps15, ATG14 and AMBRA1) and maturing stages
(composed of PIK3C3/Vps34, Beclin-1, PIK3R4/Vps15 and
UVRAG) of autophagosomes (Nakamura and Yoshimori, 2017).
Conversely, both ULK and PI3KCIII complexes are activated
by AMPK-dependent phosphorylation (Kim et al., 2011, 2013;
see scheme in Figure 3). A third mechanism involves mTORC1
phosphorylation of transcription factor TFEB, which prevents its
translocation to the nucleus and therefore the transcription of
several ATGs and lysosomal proteins (see scheme in Figure 4).
ROLE OF mTOR IN ISCHEMIA/HYPOXIA
Different Approaches in Vitro and in Vivo
Cerebral ischemia, also known as ischemic stroke, is a sudden
vascular accident that occurs when blood flow is reduced
(transiently or permanently) to any cerebral artery by a clot,
thrombus or atherosclerotic plaque. Globally, it is the second
leading cause of death and the leading cause of adult long-
term disability, and thus has a great social and economic
impact (Thrift et al., 2014). Age is one of the most influencing
factors related to incidence of stroke (Benjamin et al., 2017),
and due to longer life expectancy, the incidence of ischemic
stroke will increase over time. There does not currently exist
any pharmacological treatment to reduce brain damage after
stroke; the only therapeutic approaches are reperfusion by
thrombolytic administration (only rtPA is approved) or surgery.
However, not all stroke patients are appropriate for reperfusion,
and only 10-20% of stroke patients receive rtPA (Lees et al.,
2010), mainly because the window to restore blood flow to a
cerebral artery is short (about 3–4 h from first symptoms) and
the risk of cerebral hemorrhage is high after this time (Lenglet
et al., 2014). The scientific community is making an intense
effort to identify possible therapeutic targets to reduce ischemic
damage and improves patient quality of life and to potentiate
the effects of reperfusion in suitable patients. However, to date
the pharmacological approaches that have been shown to be
neuroprotective, reducing damage after stroke in animal models,
have failed in humans (Cheng et al., 2004).
There are two different approaches to analyze the effects of
ischemia and test potential neuroprotective compounds. The
most commonly used in vitro model depends on oxygen and
glucose deprivation (OGD) of primary cultured neurons or
glial cells. This allows for precise control of duration of OGD
exposure, permitting the study (even at molecular levels) of
ischemia in each neural cell type at different times of injury. The
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FIGURE 4 | Cellular processes mTORC1 mediated. mTORC1 play a central role in cellular metabolism controlling some anabolic (synthesis of proteins and nucleotide,
lipogenesis) and catabolic (autophagy) processes.
most common in vivomodel used is occlusion of middle cerebral
artery (MCAO), which can mimic patients that have been treated
after stroke (transient MCAO; tMCAO), or those who were not
treated (permanent MCAO; pMCAO).
After hypoxia or ischemic conditions, the brain suffers a series
of events collectively called “ischemic cascade,” including energy
failure, excitotoxicity, neuroinflammation and delayed neuronal
death by apoptosis (Pérez-Alvarez and Wandosell, 2013; Perez-
Alvarez and Wandosell, 2016). The reduction in blood flow
to the brain decreases availability of nutrients, oxygen, and
energy, compromising neural cell viability, and the degree of
cell damage depends on the duration and severity of ischemia.
Accordingly, the brain is especially sensitive to energy and
nutrient fluctuations for several reasons: (1) the brain is highly
dependent on glucose and oxygen from the blood (it is estimated
that it consumes more than 50% of total glucose in the body);
(2) neurons use glucose as a primary energy source (although
astrocytes can partially supplement nutrient requirements for
neurons); and (3) release of energy from glucose relies on
oxidative metabolism. Thus, it is reasonable to conclude that
mTORC1 may play a key role after ischemia, in the balance
between anabolic and catabolic processes needed to protect
neurons from death.
Some studies have confirmed that after brain ischemia,
the reduction (via blockage) of oxygen, glucose and growth
factors triggers a decrease in mTORC1 activity. A dramatic
inhibition of neuronal mTORC1 has been described after
ischemia, through diminished activity of the PI3K/Akt pathway
in both in vitro and in vivo models (Dutta et al., 2015; Mateos
et al., 2016). Consequently, evidence supports lower mTORC1
phosphorylation of p70S6K, with a subsequent inhibition of its
activity (Hwang and Kim, 2011; Dutta et al., 2015; Mateos et al.,
2016). Studies with p70S6K1/2−/− mice confirmed a role for
this protein in brain protection after pMCAO (Pastor et al.,
2009).
Glial cells are also affected by cerebral ischemia; after
OGD/reperfusion, activation of the mTOR pathway is
key to restore proliferation, migration and production of
inflammatory mediators by astrocytes and microglia (Chong
et al., 2007; Li et al., 2015). In pathological situations, a
decrease in mTORC1 activity using rapamycin reduced
glia scar formation after traumatic spinal cord injury,
preventing astrocytes growth and proliferation (Goldshmit
et al., 2015). Anoxic conditions reduce p70S6K1 mRNAs in
astrocyte cultures, leading to cell death after OGD by an
unbalance of pro- and anti-apoptotic factors and increased
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ROS (Pastor et al., 2009). Therefore, some negative aspects
of ischemic injury related to cellular death are triggered by
deregulation of PI3K/Akt/mTORC, and increased activity of this
pathway has proven to ameliorate the damage (see scheme in
Figure 5).
It is well known that ischemic conditions induce transcription
of HIF-1, a transcriptional factor that is a heterodimer composed
of HIF-1α and HIF-1β. HIF translocates to the nucleus and can
reprogram gene expression to facilitate cell survival in hypoxic
conditions. The main process triggered by HIF consists of a
shift from oxygen-consuming oxidative phosphorylation to
oxygen-independent glycolysis, ensuring continued generation
of ATP during hypoxia (reviewed in Chen and Sang, 2016).
HIF-1 activity is determined by HIF-1α, thus the amounts
of available HIF-1α are precisely regulated by a nutrient-
and oxygen-dependent mechanism. In normal conditions,
physiological oxygen levels induce HIF-1α ubiquitination and
proteasomic degradation. In contrast, the low levels of oxygen,
glucose and amino acids during hypoxia induce AMPK activity,
stabilizing HIF-1α in combination with chaperones (such as
Hsp90), increasing HIF-1 activity. A connection between HIF-1
and mTORC1 has been reported: Isoflurane preconditioning,
which reduces neurological deficits, infarct volume, brain edema
and apoptosis after ischemia induction, up-regulated HIF-1α
expression via Akt/mTOR/p70S6K activation (Yan et al., 2016).
Although translation of HIF-1α is not affected by inhibition of
mTORC1, some reports have described an increment of HIF-1α
synthesis when mTORC1 activity was increased (Hudson et al.,
2002; Brugarolas et al., 2004; Bernardi et al., 2006; see scheme in
Figure 5).
FIGURE 5 | mTORC1 and cerebral ischemia. The scheme represent some of the effects of cerebral ischemia on mTORC1 activity according with the available data.
Ischemia induces mTORC1 inhibition. These situation promotes a reduction in protein synthesis and an increase autophagy and in some situations apoptosis. The
increment in autophagy, almost at short time, may induce an increment in cell viability. However, autophagy imbalance or ischemic persistence may trigger apoptosis.
The balance of this process via mTORC1, determinates the final destiny of hypoxia affected cells.
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Some Neuroprotective Agents Regulate
mTOR Activity
Many data support the hypothesis that PI3K-Akt-mTORC1
represents a major contribution, in almost all cell types, to
controlling cell survival and proteostasis. In fact, in many
neurodegenerative diseases, dysfunction of this pathway has been
reported (Heras-Sandoval et al., 2014; Perluigi et al., 2015; Zhao
et al., 2015). As a consequence, recovery or enhancement of this
pathway has been proposed as a therapeutic strategy, with targets
ranging from PI3K, Akt, and GSK3 to mTORC1 (Shimobayashi
and Hall, 2014).
Considering the diversity of pathologies affecting the CNS and
the broad processes regulated by mTORC, below is presented
an analysis of the role of mTORC1 as a regulator of macro-
autophagy and neuroprotection, using an acute damage disease
model, such as ischemic stroke. The role of mTORC1 as a
neuroprotective target in ischemia models is still a controversial
matter. Some contradictory data have been reported in relation
to beneficial or detrimental effects of autophagy induction in
the context of cerebral ischemia (Buckley et al., 2014; Chauhan
et al., 2015; Luo et al., 2015; Zhang et al., 2017). Indeed,
beneficial effects have been described after ischemic brain injury
by reducing autophagy (Guo et al., 2014; Wang et al., 2016;
Jiang et al., 2017; Zhang et al., 2017). Moreover, have been
reports some improvement in pathophysiological parameters by
increasing autophagy before ischemic damage (Yin et al., 2012;
Chauhan et al., 2015; Luo et al., 2015). The use of rapamycin
and chloroquine in mouse models to induce or block autophagy,
respectively, immediately after stroke indicated that both increase
and decrease of autophagy reduced the size of the infarct area
(Buckley et al., 2014). However, only increased autophagy before
damage or at the same time, improved neurological score, and
reduced neuronal death to a greater extent (Buckley et al., 2014;
Chauhan et al., 2015).
Some data using an “ischemic tolerance” or “ischemic
preconditioning” paradigm in the heart indicate that sublethal
ischemic insults prior to real damage may be protective,
permitting the hypothesis that a protective endogenous
mechanism triggered after a moderate brain ischemia may make
tissue resistant to a more severe ischemic insult (Lee et al., 2000).
Some evidence supports that the mTORC1 pathway is a mediator
of this neuroprotective process by inducing autophagy, and
Tsc1 has been revealed as a key player. Overexpression of Tsc1
conferred protection to hippocampal neurons after OGD by
inducing efficient autophagic flux. However, downregulation of
TSC1 triggered autophagosome accumulation, compromising
autophagy (Papadakis et al., 2013). However, not only has the role
of mTORC1 in autophagy been reported to be neuroprotective in
the paradigm of ischemic tolerance, but its inhibition promoted
this protective mechanism in part through changes in translation
(Wouters and Koritzinsky, 2008).
Treatment with rapamycin after 1 h of hypoxic or ischemic
conditions in an in vitro model of OGD improved neuronal
survival after damage (Fletcher et al., 2013), and rapamycin
preconditioning before tMCAO improved neurological deficits
and reduced infarct area and brain edema (Yin et al., 2012).
Reports on the effects of pre-ischemic rapamycin administration
have revealed a parallel between increased autophagy and
decreased mTORC1 activity, diminishing apoptosis, significantly
reducing infarct area and oxidative stress, and improving
behavioral outcomes after ischemia (Chauhan et al., 2011; Chong
et al., 2013).
Nevertheless, as we have commented previously, some reports
demonstrated detrimental effects of autophagy induction in
rodents models of cerebral ischemia (Guo et al., 2014; Jiang
et al., 2017; Zhang et al., 2017). These controversial results
must be analyzed carefully taking into account the moment
in which autophagy is induced or blocked in animal models.
Autophagy induction before or just after ischemic damage, result
in beneficial effects measured as improvement of neurological
score, reduction of infarct area or diminution of brain edema
(Yin et al., 2012; Chauhan et al., 2015; Luo et al., 2015). Opposite
results have been obtained when autophagy induction was later
(after almost 1 h of ischemic damage) (Guo et al., 2014; Jiang
et al., 2017; Zhang et al., 2017).
In some mouse models, treatment with agents that increase
the activity of the PI3K/Akt/mTORC pathway (before/after
induction of ischemia) has been shown to be neuroprotective,
reducing ischemic damage and improving neurological score
(Guo et al., 2014; Zheng et al., 2014; Lisi et al., 2015; Mateos et al.,
2016; Chen et al., 2017).
Taking into account these data, we can conclude that after
ischemic damage the accessibility of growth factors decrease,
the canonical pathway PI3K/Akt/mTORC1 is downregulated and
consequently autophagy may be enhanced.
However, authophagy induction before ischemiamakes neural
tissue more resistant to damage, while a sustained increment
of autophagy or a greater inhibition of mTORC1 or lysosomal
proteases activity after ischemia induce detrimental effects related
with neuronal and/or glia, survival.
In conclusion autophagy could be considered an endogenous
protective mechanism, at some extent, triggered after ischemic
damage, because downregulation of PI3K/Akt/mTORC1
pathway. However, sustained increment of autophagy over the
time or an excess of “levels” of autophagy, or sustained inhibition
of PI3K/Akt/mTORC1 are detrimental for neuronal survival.
This highlights the importance of a fine tune control of both: the
autophagy process and mTORC1 activity, to maintain neuronal
viability in ischemic conditions.
An important neuroprotective element used in ischemia
models is estradiol, which has been reputed to reduce ischemic
damage either pre- or post-insult. In general, estrogens function
via different types of response: “genomic actions” regulated
by classical estrogen receptors (ERs); “non-genomic” or “rapid
actions” initiated by ERs and membrane-associated receptors;
and ER-independent mechanisms, such as the antioxidant effects
reported by estradiol (for a review see: Mann et al., 2007; Arevalo
et al., 2015). In addition to the “classical” nuclear actions, rapid
estrogen effects have been described that occur within minutes
and thus cannot be attributed to genomic mechanisms (Toran-
Allerand et al., 2002; Raz et al., 2008). In fact, estradiol may
activate MAPK/Erk (Singh et al., 1999), PI3K (Honda et al.,
2000) and Akt (Cardona-Gomez et al., 2004; Mendez et al.,
2006), among other cytoplasmic elements, using either classical
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or membrane-associated receptors (for review see: Arevalo et al.,
2015). It has been reported that estradiol may have therapeutic
effects in ischemia models, as injection (even post-ischemia)
reduced the damage area, at least in part due to activation of
the PI3K/Akt pathway (Koh, 2007; Pérez-Álvarez et al., 2012;
Pérez-Alvarez and Wandosell, 2013). This strongly support the
hypothesis that estradiol may control the activity of mTORC1 via
cytoplasmic signaling (Varea et al., 2013).
Another important neuroprotective mechanism after cerebral
ischemia is angiogenesis, the generation of new capillaries,
which has been revealed to be a critical contributor to
tissue recovery. Postmortem analysis of ischemic brain tissue
revealed a significant increase in the number and size of
microvessels in affected areas compared to the contralateral
hemisphere, associated with longer patient survival (Krupinski
et al., 1994). Angiogenesis after ischemic insult contributes
to improved cerebral blood flow in the penumbra and
reduces brain damage. mTORC1 has been identified as a
potent mediator in this process, as mTORC1 activation
increases VEGF levels (via the PI3K/Akt/mTORC1 pathway)
by inducing its transcription in neurons (Chen et al., 2012;
Mateos et al., 2016). This angiogenic enhancement reduces
ischemic damage by decreasing the affected area and resulted
in a higher neurological score in animal models of stroke
(Mateos et al., 2016). Indeed, it has been reported that
rapamycin administration reduced VEGF induction, preventing
angiogenesis and increasing apoptotic cell death (Stahl et al.,
2008).
At a pharmacological level, the role of statins must be
mentioned, having been reported to have pleiotropic effects
on neuroprotection. Statins inhibit HMG-CoA reductase,
generating not only a reduction of cholesterol but also
other intermediate metabolites essential for the formation
of isoprenoids, such as geranyl pyrophosphate or farnesyl
pyrophosphate, that are incorporated into such proteins as the
Ras and RhoA families, among others, which play key roles in
cellular signaling.
A second described effect for statins is enhancement of
angiogenesis. Atorvastatin promoted angiogenesis, boosting
functional recovery after stroke through a mechanism increasing
VEGF, BDNF, eNOs, and some synaptic proteins such as
glutamate receptor GluN1 or GluN2B (Cespedes-Rubio et al.,
2010; Gutierrez-Vargas et al., 2014) in a mouse MCAO model
(Brouet et al., 2001; Chen et al., 2003). Some of these actions
are mediated by activation involving, directly or indirectly, the
PI3K/Akt/mTORC1 pathway (Kureishi et al., 2000; Yang et al.,
2015).
CONCLUSIONS
PI3K/Akt/mTORC1 is an important pathway that is implicated
in some neurodegenerative diseases and also in recovery from
ischemic stroke. Thus, genetic or pharmacologic enhancement of
this pathway should be considered a potent neuroprotective tool,
though the exact role of mTORC1 after stroke and its connection
with regulation autophagy must be more carefully investigated
to clarify controversial data. For instance, temporal studies
are needed since it is very possible that the role of mTORC1
and autophagy depends on duration as well as the severity of
nutrient/growth factor/oxygen deprivation. Accordingly, more
work should be carried out to clarify whether alternative methods
to enhance neuronal autophagy have additional therapeutic
benefits after brain ischemia.
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